1. Introduction
Since the discovery of the protease within the cells that play pivotal roles in immunological and hematological cascades, tryptase has drawn attention as a versatile, easily obtainable and reliable biomarker. Since the 1980s, scientific interest has primarily focused on allergic and genetic mastocyte-related disorders, particularly mastocytosis. However, more recently, tryptase has emerged as a valuable diagnostic and prognostic laboratory indicator in a variety of clinical conditions [
1].
Despite vast amounts of data covering the biochemical characteristics of tryptase and its relevance in scientific research, the clinical implications for its use in everyday practice remain scarce.
The objective of this paper is to provide a thorough insight into tryptase biology and its role in the pathophysiology of hypersensitivity reactions and mast cell-related conditions, while also highlighting its growing number of clinical implications (represented in
Table 1).
2. Method
We performed a comprehensive literature search of the PubMed/Medline and Scopus databases up to 1 May 2024, using the following search terms: tryptase, mast cell-related conditions, anaphylaxis, hypersensitivity and drug allergy.
Since 1940, over 640 papers have been dedicated to evaluating the various clinical roles and practical uses of tryptase. Following the detailed analysis of the available review papers and case reports, 45 articles were picked by the authors. Although there were no restrictions regarding the publication date, the majority of the selected papers were found to be contemporary, comprehensible, clinically relevant to date and have been published in the past twenty years. All of the articles have been published in English. Two clinical cases presented in this paper involved patients that were treated at the Clinic of Allergology and Immunology of the University Clinical Center of Serbia during the past five years.
3. Serum Tryptase: Biology and Pathophysiology
Mast cells (MCs) are long-lived, tissue-resident cells that play important roles in hypersensitivity and allergic reactions, as well as inflammatory responses. They are bone marrow-derived from hematopoietic lineage, originating from the CD34+/CD117+pluripotent progenitor cells [
1]. Their maturation and differentiation take place throughout the body, under the influence of the c-KIT ligand stem cell factors, along with the growth factors provided by the microenvironment of the peripheral tissue where MCs are destined to reside [
2]. Although mature MCs can be collocated to the blood vessels of any epithelial or mucosal tissue, most MCs are found at the crossroads between the host and the foreign antigen (skin, respiratory, gastrointestinal tract and ocular tissues).
Mature MCs contain numerous cytoplasmic granules that store pro-inflammatory mediators, including histamine, proteoglycans like heparin and many neutral serine proteases such as tryptase. Upon mast cell activation and degranulation, the contents of these granules are released, leading to tissue damage during immediate hypersensitivity reactions [
1,
2].
Although basophiles contain similar granular content, they have approximately 500 times less tryptase than mast cells. Consequently, elevated serum tryptase levels are considered to be a specific indicator of mast cell activation, leading to it being commonly referred to as mast cell-derived tryptase.
Tryptase is a serine esterase with four non-covalently bound subunits. There are four known types of human tryptase: α, β, γ and δ, but only α and β are known to be clinically relevant to date. Unstimulated tissue mast cells continuously secrete immature monomeric α and β-protryptase, which constitute the serum basal tryptase. The mature forms of tryptase are only released following mast cell activation [
2].
While the exact function of enzymatically inactive protryptase (stored in the endoplasmic reticulum) is still unknown, many studies have highlighted the biological activities of tryptase tetramers. These activities include roles in the acute phase of MC degranulation and in the late phase of inflammation [
2,
3].
3.1. Tryptase Measurement
In clinical practice, measuring total serum tryptase levels as an MC biomarker is a simple and affordable method. This is typically performed by a commercial in vitro quantitative test using a noncompetitive two-site fluorescent enzyme immunoassay (Phadia, ImmunoCAP/Portage, MI, USA). The units used are micrograms per liter (µg/L) or the equivalent nanogram per milliliter (ng/mL) [
4,
5]. Serum and plasma are the recommended samples for measuring levels of tryptase. In some cases, other bodily fluids, such as tears, saliva, nasal secretions, sputum or feces can be used as well. Urine is not suitable for the analysis, as tryptase is not excreted through the urinary tract [
6]. False-positive results due to interference with the rheumatoid factor have been reported and yet overcome by adding heterophilic antibody suppressors and the F(ab’)2 detection antibody [
7].
3.2. Serum Baseline Tryptase: Normal Range, Determinants and Clinical Implications
There is an important difference between sBT, which represents the total body MC burden, and the transient peak tryptase or sAT level following the MC degranulation [
6].
Since the introduction of the total tryptase assay, which has been used worldwide since 1994, the cut-off value or the 95th percentile value for sBT has repeatedly been going down from the initial 13.5 µg/L (1994) to the current 8.4 µg/L (2022). This change can be explained by the major discovery of an autosomal dominant genetic disorder called hereditary alpha-tryptasemia (HαT) and the improved detection of other MC-related conditions [
6].
Based on the working classification, the predisposing factors are divided into major (strong), which cause an increase in sBT, and minor (weak) determinants, which cause sBT variation within the reference range [
6].
Inherited conditions, such as hereditary HαT, are reported as major determinants. This was confirmed by Waters et al., since almost two-thirds of the fifty-eight patients enrolled in their study with sBT levels of 11.5 μg/L and greater have been diagnosed with HαT [
8]. HαT is an autosomal dominant genetic trait with variable clinical penetrance that is caused by an excess of copies of the TPSAB1 gene that encodes α tryptase. This condition exhibits a gene dosage effect with an estimated rise of approximately 9 ng/mL in sBT levels for every additional copy of the TPSAB1 gene [
9]. Patients with this genetic trait have levels of sBT above 8 µg/mL and have a 3- to 4-fold increased risk of developing severe anaphylaxis, as reported by various studies [
10,
11]. Meanwhile, the majority of patients with systemic mastocytosis carry the somatic D816V mutation in the KIT gene [
12,
13,
14,
15].
The other major determinants include other MC conditions such as mastocytosis, myeloid disorders, atherosclerosis, acute coronary syndrome, chronic kidney disease (CKD) and gastrointestinal disorders, such as IBS, inflammatory bowel disease, eosinophilic esophagitis, hepatocellular carcinoma and parasitic infections (details listed in
Table 1) [
15,
16,
17,
18,
19,
20,
21,
22,
23,
24,
25,
26,
27,
28]. The minor determinants are not as well defined and include age, sex and lifestyle factors. Therefore, an sBT level above 8.4 µg/mL should elicit further investigation [
15].
For patients with a measured sBT greater than 11.5 ng/mL, a clinical algorithm recommended by Waters et al. includes conducting a complete blood count with a leukocyte count, creatinine and estimated glomerular filtration rate measurement, TPSAB1 genotyping, 24 h urinary methylhistamine detection and a KIT p.D816V allele-specific PCR of a blood sample [
8,
14,
15]. All patients with persistent elevation of sBT above 20 ng/mL must be referred to a hematologist for further examination [
15].
On the other hand, diagnosing conditions such as anaphylaxis requires correlating the serum acute tryptase (sAT) level with the measured baseline tryptase (sBT) level. Since MCs are located in peripheral tissue and not the bloodstream, there is a delay of 20 to 30 min from the onset of symptoms to the detection of tryptase in the blood, with the levels peaking approximately 1 h after MC activation and symptom onset. To support the clinical diagnosis of anaphylaxis, at least two serum tryptase measurements need to be taken at the appropriate time (
Figure 1) [
6,
29].
Interestingly, the measurement of the tryptase level can also be used in forensic medicine as a promising diagnostic biomarker of sudden death caused by anaphylactic shock, notably when levels of post-mortem tryptase are greater than 30.4 μg/L [
30,
31].
4. The Role of Tryptase in Allergic Diseases
4.1. Type I Hypersensitivity Reactions
According to the latest World Allergy Organization (WAO) definition, anaphylaxis is a severe, life-threatening systemic hypersensitivity reaction characterized by a rapid onset with potentially life-threatening airway, breathing or circulatory issues, typically accompanied by skin and mucosal changes [
32].
The diagnostic criteria for anaphylaxis proposed by the European Academy of Allergy and Clinical Immunology (EAACI) include the acute onset of the allergic reaction following the immediate exposure to a known allergen involving the skin and mucosal tissue, both in combination with respiratory and cardiovascular compromising, hypotension or a sudden drop in blood pressure (BP) as the sole criteria [
33].
The EAACI task force suggests measuring serum tryptase levels 30 min to 2 h after the onset of symptoms, as well as obtaining sBT at least 24 h after the complete symptom resolution, to support the diagnosis of anaphylaxis [
34,
35]. These timings reflect the half-life of tryptase, which is approximately 2 h, with levels peaking 1 to 2 h after the onset and usually returning to baseline within 6 to 8 h. If a prior sBT or a blood sample collected before the anaphylaxis reaction is available, it can also be used to determine the change in tryptase levels. There is a widely used formula, known as the 20 + 2 rule, recommended for calculating a personalized cut-off value: 1.2 × sBT = 2 [
36]. A rise in sAT levels greater than the value defined by the equation had a high specificity and positive predictive value, with a moderate negative predictive value and sensitivity (91%, 98%, 44% and 78%, respectively) [
15].
In 2022, Allyson et al. introduced a new model using an sAT/sBT ratio of 1.685, which maximizes both specificity and sensitivity for confirming anaphylaxis in all patients. Their study demonstrated that an sAT/sBT ratio of 1.685 or higher is positively correlated with the clinical diagnosis of anaphylaxis, achieving 95% sensitivity and specificity [
15].
It is important to emphasize that serum tryptase is not always elevated in anaphylaxis, especially in food triggers across all ages. Therefore, failing to find an elevated tryptase level does not exclude anaphylaxis [
33].
In real-life clinical scenarios, several factors influence the process, including the rapidity of clinical development, the time between the onset of symptoms and the intervention by the emergency department or medical team, as well as the time it takes to stabilize the patient before additional diagnostic tests can be performed. All this affects the timing of the acute serum tryptase sampling, but it should not be disregarded. Previous studies have shown the improved sensitivity of sAT upon serial measurement. The high specificity of sAT makes it a valuable test to distinguish anaphylaxis from its “mimics,” even if it only serves to confirm a past event [
37].
4.1.1. Tryptase Values in Insect Venom Allergy
Hymenoptera venom allergy (HVA) is a form of IgE-mediated degranulation of mast cell and basophils [
38,
39]. Clinical manifestations of HVA can range from large local reactions (LLRs) at the sting site, characterized by localized swelling lasting more than 24 h and exceeding a diameter of 10 cm, to systemic sting reactions (SSRs). SSRs can vary from moderate reactions such as generalized urticaria, angioedema, dizziness, dyspnea and nausea to severe reactions such as shock, loss of consciousness and respiratory or cardiac arrest [
40]. The diagnosis of HVA is based on a detailed clinical history and relevant venom by in vivo or in vitro testing [
41]. It is recommended to measure the levels of sBT in all patients with a positive history of SSR to identify those at a higher risk of developing severe reactions. Patients can be divided into groups based on their risk of developing SSR using their sBT levels: the low-risk group, with tryptase levels lower than 4 μg/L; the intermediate-risk group, with levels ranging from 4 to 7.5 ng/mL and the high-risk group with levels greater than 7.5 μg/L [
42]. A measured value greater than 11.4 µg/L often indicates underlying mastocytosis, which is more frequent in HVA patients than in the general population and is shown to be an independent risk factor for more severe SSR [
43]. Therefore, EAACI guidelines recommend prolonged venom immunotherapy (VIT) in all patients with mastocytosis and/or sBT higher than 11.4 µg/L because of a higher risk of treatment failure and a higher chance of relapse after stopping VIT, which includes fatal reactions. It still remains unclear whether VIT should be lifelong for those patients [
44].
4.1.2. Drug Allergies and Tryptase
Drug hypersensitivity reactions (DHRs) can be classified as either immediate or delayed, based on their onset time. Immediate DHR is usually IgE-mediated and occurs within 1–6 h after drug administration, following the binding to the appropriate cell receptor that stimulates the release of various mast cell mediators, including tryptase. DHR can also be non-IgE-mediated, leading to direct mast cell degranulation through a different pathway. Clinical manifestations of immediate DHR include urticaria, angioedema, conjunctivitis, bronchospasm or even anaphylaxis [
37].
Anaphylaxis usually occurs suddenly and with severe symptoms, requiring prompt recognition and treatment. Considering that different pathological mechanisms leading to drug-induced anaphylaxis can be similar, the presentation alone cannot solemnly confirm the type of reaction. Therefore, measuring tryptase levels is considered to be a helpful tool for timely diagnosis. These findings are particularly important for patients who develop perioperative anaphylaxis [
45].
4.1.3. Use of Tryptase in Perioperative Anaphylaxis
Perioperative anaphylaxis (PA) is a form of systemic anaphylactic reaction caused by antibiotics, neuromuscular blocking agents (NMBAs), chlorhexidine or latex. It is frequently unrecognized due to various factors: a personal history of diseases, lack of adequate symptom description due to a sedated or anesthetized patient, similar pharmacodynamic characteristics of anesthetics and anaphylaxis symptoms. These factors make PA a medical emergency which is very difficult to treat [
45].
The estimated incidence of PA varies between 1:6000 and 1:20,000 cases, with a mortality rate of up to 9% [
21]. Many studies have identified NMBA as the most common trigger, while others state that antibiotics are the most frequent cause [
33,
45].
Mast cell-derived tryptase measurement can be helpful in confirming the diagnosis of PA, although the time it takes to run this test is a limiting factor for immediate diagnosis [
15]. According to EAACI recommendations, measuring sAT (0.5–2 h after the initiation of the symptoms) and sBT (before onset or at least 24 h after resolution of the symptoms) levels increases the diagnostic accuracy of PA, as well as the number of referrals to an allergist for a further workup [
34].
Clinical Case No. 1
A female patient was admitted to the vascular surgery department for brachycephalic truncus reconstruction and was administered Midazolam, Propofol, Fentanyl, Rocuronium, Sevoflurane and Cefuroxime. Almost immediately, she experienced bronchospasm, followed by hemodynamic instability and resistant hypotension. The patient was treated with adrenalin, corticosteroids, antihistamines and bronchodilators, which resulted in a favorable therapeutic response. Immunological analyses revealed an elevated sAT level of 18.9 µg/L (reference range is 0–11 mcg/L) compared to an sBT level that was 5.69 µg/L, confirming the assumed diagnosis of PA. The specific IgE testing for cephalosporins was negative. Considering the patient’s history of previous surgical procedures under general anesthesia, which could have caused the initial sensitization, in vivo drug provocation tests with selected alternative intravenous anesthetics were performed. The tests for Remifentanyl and Hypnomidate were negative. However, a positive intradermal test with Midarine lead to the conclusion that the NMBAs were the most probable cause of the PA. Therefore, it was concluded that NMBAs should be avoided or replaced in future procedures.
4.1.4. Tryptase and Iodinated Contrast Media Hypersensitivity Reactions
Contrast media agents are a rare cause of potentially severe anaphylactic reactions. Due to their wide use and broad spectrum of clinical indications, iodinated contrast media agents (ICMs) are the most common culprits. The type of contrast media agent and its osmolarity and the dosage and rapidness of the application play an important role when it comes to both allergic and non-IgE-mediated reactions that can be both responsible for the MC degranulation and serum tryptase level rise. However, there are many contributing factors such as advanced age and comorbidities (allergic and cardiovascular diseases) that may predispose a certain individual to an unfavorable outcome.
Clinical Case No. 2
A female patient undergoing a computed tomography scan (CT) of the abdomen experienced a severe reaction during the administration of the ICM. She lost consciousness, developed cyanosis with agonal breathing, had non-palpable peripheral pulses and her blood pressure was immeasurable. Immediately, she was intubated alongside the continued resuscitation measures of electro cardioversion, crystalloid infusion and vasopressor support, including adrenalin. Due to her clinical presentation of generalized erythema and periorbital edema, she was treated with corticosteroids and antihistamines. The diagnosis of anaphylaxis was confirmed by serum tryptase analysis (sAT level was 160 µg/L and sBT level 11 µg/L). The patient had an atopic constitution and a previous medical history of allergic rhinitis and asthma, as well as nasal polyposis with sensitization to house dust mites and tree pollen. Despite having no prior drug hypersensitivity reactions and having undergone CT pulmonary angiography a year earlier without incident, premedication was not administered. The patient spent two weeks in the intensive care unit but succumbed to a severe brain injury. This case emphasizes the importance of detailed overall clinical and risk assessments, critical patient selection, timely premedication and therapeutic intervention.
5. Conclusions
Based on the thorough literature research and the clinical experience, illustrated by two cases from our own clinical practice, we have arrived at the following conclusions:
- -
In all suspected cases of MC activation and degranulation, a timely tryptase measurement is required to confirm anaphylaxis and differentiate it from its mimics.
- -
The laboratory analysis is time-consuming but should not be neglected, nor should the initial treatment of the acute reaction be postponed while waiting for the said result.
- -
Tryptase levels determined upon suspected drug allergy may help with risk stratification and the need for premedication during imaging procedures and surgical interventions.
- -
An elevated sBT level in HVA is associated with a higher risk of anaphylactic reactions and therefore requires a prolonged VIT.
- -
The constant increase in the number of clinical conditions associated with a noticeable elevation of the sBT level requires a multidisciplinary approach and collaboration, as well as further scientific research and the continuation of medical education.
Author Contributions
Conceptualization, V.T.-S., I.O.P. and S.R.; methodology, I.O.P. and V.T.-S.; investigation, I.O.P., S.R., D.K., J.S., N.K. and A.V.; resources, I.O.P., S.R., D.K., J.S., N.K. and A.V.; data curation I.O.P. and N.K.; writing—original draft preparation, I.O.P., S.R., D.K. and J.S.; writing—review and editing, I.O.P., S.R., D.K., J.S., N.K., A.V. and V.T.-S.; visualization, I.O.P., S.R., N.K. and A.V.; supervision, V.T.-S. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- Gilfillan, A.M.; Austin, S.J.; Metcalfe, D.D. Mast Cell Biology: Introduction and Overview. In Mast Cell Biology; Springer: Boston, MA, USA, 2011; pp. 2–12. [Google Scholar]
- Krystel-Whittemore, M.; Dileepan, K.N.; Wood, J.G. Mast Cell: A Multi-Functional Master Cell. Front. Immunol. 2016, 6, 620. [Google Scholar] [CrossRef]
- Kayne, V.; Kam, P.C.A. Mast cell tryptase: A review of its physiology and clinical significance. Anaesthesia 2004, 59, 695–703. [Google Scholar]
- Phadia, A.B. ImmunoCAP(TM) Tryptase. 2018. Available online: https://dfu.phadia.com/Data/Pdf/5bfd303689c2320848d8449f.pdf (accessed on 15 April 2024).
- Sheldon, J.; Philips, B. Laboratory investigation of anaphylaxis: Not as easy as it seems. Anaesthesia 2015, 70, 1–5. [Google Scholar] [CrossRef] [PubMed]
- Michel, M.; Klingebiel, C.; Vitte, J. Tryptase in type I hypersensitivity. Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol. 2023, 130, 169–177. [Google Scholar] [CrossRef]
- Vitte, J.; Sabato, V.; Tacquard, C.; Garvey, L.H.; Michel, M.; Mertes, P.-M.; Ebo, D.G.; Schwartz, L.B.; Castells, M.C. Use and Interpretation of Acute and Baseline Tryptase in Perioperative Hypersensitivity and Anaphylaxis. J. Allergy Clin. Immunol. Pract. 2021, 9, 2994–3005. [Google Scholar] [CrossRef]
- Waters, A.M.; Park, H.J.; Weskamp, A.L.; Mateja, A.; Kachur, M.E.; Lyons, J.J.; Rosen, B.J.; Boggs, N.A. Elevated Basal Serum Tryptase: Disease Distribution and Variability in a Regional Health System. J. Allergy Clin. Immunol. Pract. 2022, 10, 2424–2435.e5. [Google Scholar] [CrossRef]
- Lyons, J.J. Inherited and acquired determinants of serum tryptase levels in humans. Ann. Allergy Asthma Immunol. 2021, 127, 420–426. [Google Scholar] [CrossRef]
- Lyons, J.J. Hereditary alpha tryptasemia: Genotyping and associated clinical features. Immunol. Allergy Clin. N. Am. 2018, 38, 483–495. [Google Scholar] [CrossRef] [PubMed]
- Kačar, M.; Rijavec, M.; Šelb, J.; Korošec, P. Clonal mast cell disorders and hereditary α-tryptasemia as risk factors for anaphylaxis. Clin. Exp. Allergy 2023, 53, 392–404. [Google Scholar] [CrossRef]
- Akin, C. Mast Cell Activation Disorders. J. Allergy Clin. Immunol. Pract. 2014, 2, 252–257. [Google Scholar] [CrossRef]
- Leru, P.M.; Anton, V.F.; Ureche, C.; Zurac, S.; Bratu, O.; Neagoe, C.D. Mast cell activation syndromes—Evaluation of current diagnostic criteria and laboratory tools in clinical practice (Review). Exp. Ther. Med. 2020, 20, 2348–2351. [Google Scholar] [CrossRef] [PubMed]
- Burks, A.W.; O’Hehir, R.E.; Broide, D.H.; Holgate, S.T.; Bacharier, L.B.; Hershey, G.K.K.; Peebles, R.S. Middleton’s Allergy: Principles and Practice; Elsevier Health Sciences: Amsterdam, The Netherlands, 2019. [Google Scholar]
- Valent, P.; Sperr, W.R.; Sotlar, K.; Reiter, A.; Akin, C.; Gotlib, J.; Horny, H.-P.; Arock, M. The serum tryptase test: An emerging robust biomarker in clinical hematology. Expert Rev. Hematol. 2014, 7, 683–690. [Google Scholar] [CrossRef] [PubMed]
- Pucar, P.A.; Randall, K.L.; Li, C.; McNaughton, E.; Hawkins, C.A. Tryptase and renal failure: A retrospective audit of routine laboratory samples. Pathology 2017, 49, S44. [Google Scholar] [CrossRef]
- Jesky, M.D.; Stringer, S.J.; Fenton, A.; Ng, K.P.; Yadav, P.; Ndumbo, M.; McCann, K.; Plant, T.; Dasgupta, I.; Harding, S.J.; et al. Serum tryptase concentration and progression to end-stage renal disease. Eur. J. Clin. Investig. 2016, 46, 460–474. [Google Scholar] [CrossRef]
- Bot, I.; Shi, G.P.; Kovanen, P.T. Mast Cells as Effectors in Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 265–271. [Google Scholar] [CrossRef] [PubMed]
- Lewicki, L.; Siebert, J.; Marek-Trzonkowska, N.; Masiewicz, E.; Kolinski, T.; Reiwer-Gostomska, M.; Targonski, R.; Trzonkowski, P. Elevated Serum Tryptase and Endothelin in Patients with ST Segment Elevation Myocardial Infarction: Preliminary Report. Mediat. Inflamm. 2015, 2015, 395173. [Google Scholar] [CrossRef] [PubMed]
- Filipiak, K.J.; Tarchalska-Krynska, B.; Opolski, G.; Rdzanek, A.; Kochman, J.; Kosior, D.A.; Czlonkowski, A. Tryptase levels in patients after acute coronary syndromes: The potential new marker of an unstable plaque? Clin. Cardiol. 2003, 26, 366–372. [Google Scholar] [CrossRef]
- Morici, N.; Farioli, L.; Losappio, L.M.; Colombo, G.; Nichelatti, M.; Preziosi, D.; Micarelli, G.; Oliva, F.; Giannattasio, C.; Klugmann, S.; et al. Mast cells and acute coronary syndromes: Relationship between serum tryptase, clinical outcome and severity of coronary artery disease. Open Hear. 2016, 3, e000472. [Google Scholar] [CrossRef]
- Wang, S.; Webster, E.; Wang, D.; Barken, D.; Gong, H.; Singh, S. Evaluation on the Diagnostic Utility of Serum Tryptase Level in Irritable Bowel Syndrome: 1333. Off. J. Am. Coll. Gastroenterol. ACG 2009, 104, S498. [Google Scholar] [CrossRef]
- De Los Ríos, C.C.; de Lucas, I.C.; Rodríguez-Valcárcel, F.C.; Pastor, M.C.; de Aparato Digestivo, S. Irritable bowel syndrome and basal serum tryptase: The correlation between subtype, severity and comorbidities. a pilot study. Rev. Esp. Enfermadades Dig. 2022, 114, 22–27. [Google Scholar] [CrossRef]
- Bridge, S.; Peterson, K. Tryptase: A New Measure (or Predictor) of the Extent of GI Involvement in Eosinophilic Esophagitis (EoE)?: 88. Off. J. Am. Coll. Gastroenterol. ACG 2012, 107, S38. [Google Scholar] [CrossRef]
- Liu, B.; Yang, M.Q.; Yu, T.Y.; Yin, Y.Y.; Liu, Y.; Wang, X.D.; He, Z.G.; Yin, L.; Chen, C.Q.; Li, J.Y. Mast Cell Tryptase Promotes Inflammatory Bowel Disease–Induced Intestinal Fibrosis. Inflamm. Bowel Dis. 2021, 27, 242–255. [Google Scholar] [CrossRef] [PubMed]
- Min, X.L.; Yang, L.; Zhang, X.M.; Zhou, Y.; Miao, N.D.; Ren, Y.J.; Xu, H.; Liu, K.; Peng, J.; Yang, K. Changes of tryptase in patients with hepatocellular carcinoma after transarterial chemoembolization. Transl. Cancer Res. 2017, 6, 1061–1067. [Google Scholar] [CrossRef]
- Lu, F.; Huang, S. The Roles of Mast Cells in Parasitic Protozoan Infections. Front. Immunol. 2017, 8, 363. [Google Scholar] [CrossRef]
- Cooper, P.J.; Schwartz, L.B.; Irani, A.; Awadzi, K.; Guderian, R.H.; Nutman, T.B. Association of Transient Dermal Mastocytosis and Elevated Plasma Tryptase Levels with Development of Adverse Reactions after Treatment of Onchocerciasis with Ivermectin. J. Infect. Dis. 2002, 186, 1307–1313. [Google Scholar] [CrossRef]
- Demoly, P.; Adkinson, N.F.; Brockow, K.; Castells, M.; Chiriac, A.M.; Greenberger, P.A.; Khan, D.A.; Lang, D.M.; Park, H.; Pichler, W.; et al. International Consensus on drug allergy. Allergy 2014, 69, 420–437. [Google Scholar] [CrossRef]
- Sun, K.J.; He, J.T.; Huang, H.Y.; Xue, Y.; Xie, X.L.; Wang, Q. Diagnostic role of serum tryptase in anaphylactic deaths in forensic medicine: A systematic review and meta-analysis. Forensic Sci. Med. Pathol. 2018, 14, 209–215. [Google Scholar] [CrossRef] [PubMed]
- Tambuzzi, S.; Gentile, G.; Boracchi, M.; Di Candia, D.; Bianchi, R.; Zoja, R. Postmortem diagnostics of assumed suicidal food anaphylaxis in prison: A unique case of anaphylactic death due to peach ingestion. Forensic Sci. Med. Pathol. 2021, 17, 449–455. [Google Scholar] [CrossRef]
- Cardona, V.; Ansotegui, I.J.; Ebisawa, M.; El-Gamal, Y.; Rivas, M.F.; Fineman, S.; Geller, M.; Gonzalez-Estrada, A.; Greenberger, P.A.; Borges, M.S.; et al. World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organ. J. 2020, 13, 100472. [Google Scholar] [CrossRef]
- Muraro, A.; Worm, M.; Alviani, C.; Cardona, V.; DunnGalvin, A.; Garvey, L.H.; Riggioni, C.; de Silva, D.; Angier, E.; Arasi, S.; et al. EAACI guidelines: Anaphylaxis (2021 update). Allergy 2022, 77, 357–377. [Google Scholar] [CrossRef]
- Vitte, J.; Amadei, L.; Gouitaa, M.; Mezouar, S.; Zieleskiewicz, L.; Albanese, J.; Bruder, N.; Lagier, D.; Mertès, P.M.; Mège, J.; et al. Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: An observational study. Allergy 2019, 74, 1157–1165. [Google Scholar] [CrossRef]
- Valent, P.; Akin, C.; Arock, M.; Brockow, K.; Butterfield, J.H.; Carter, M.C.; Castells, M.; Escribano, L.; Hartmann, K.; Lieberman, P.; et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal. Int. Arch. Allergy Immunol. 2012, 157, 215–225. [Google Scholar] [CrossRef] [PubMed]
- Baretto, R.L.; Beck, S.; Heslegrave, J.; Melchior, C.; Mohamed, O.; Ekbote, A.; Huissoon, A.P.; Krishna, M.T. Validation of international consensus equation for acute serum total tryptase in mast cell activation: A perioperative perspective. Allergy 2017, 72, 2031–2034. [Google Scholar] [CrossRef] [PubMed]
- Buka, R.J.; Knibb, R.C.; Crossman, R.J.; Melchior, C.L.; Huissoon, A.P.; Hackett, S.; Dorrian, S.; Cooke, M.W.; Krishna, M.T. Anaphylaxis and Clinical Utility of Real-World Measurement of Acute Serum Tryptase in UK Emergency Departments. J. Allergy Clin. Immunol. Pract. 2017, 5, 1280–1287.e2. [Google Scholar] [CrossRef] [PubMed]
- Antonicelli, L.; Bilo, M.B.; Bonifazi, F. Epidemiology of hymenoptera allergy. Curr. Opin. Allergy Clin. Immunol. 2002, 2, 341–346. [Google Scholar] [CrossRef]
- Turner, P.J.; Campbell, D.E.; Motosue, M.S.; Campbell, R.L. Global Trends in Anaphylaxis Epidemiology and Clinical Implications. J. Allergy Clin. Immunol. Pract. 2020, 8, 1169–1176. [Google Scholar] [CrossRef]
- Sturm, G.J.; Varga, E.M.; Roberts, G.; Mosbech, H.; Bilo, M.B.; Akdis, C.A.; Antolín-Amérigo, D.; Cichocka-Jarosz, E.; Gawlik, R.; Jakob, T.; et al. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy 2017, 73, 744–764. [Google Scholar] [CrossRef]
- Blank, S.; Grosch, J.; Ollert, M.; Bilò, M.B. Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes. Front. Immunol. 2020, 11, 579409. [Google Scholar] [CrossRef]
- Farioli, L.; Losappio, L.M.; Schroeder, J.W.; Preziosi, D.; Scibilia, J.; Caron, L.; Nichelatti, M.; Pastorello, E.A. Basal Tryptase Levels Can Predict Clinical Severity in Hymenoptera Venom Anaphylaxis and Ischemic Cardiovascular Disorders. J. Investig. Allergol. Clin. Immunol. 2019, 29, 162–164. [Google Scholar] [CrossRef]
- Bonadonna, P.; Scaffidi, L.; Boni, E. Tryptase values in anaphylaxis and insect allergy. Curr. Opin. Allergy Clin. Immunol. 2019, 19, 462–467. [Google Scholar] [CrossRef]
- Lee, A.Y.S. Elevated Serum Tryptase in Non-Anaphylaxis Cases: A Concise Review. Int. Arch. Allergy Immunol. 2020, 181, 357–364. [Google Scholar] [CrossRef] [PubMed]
- Admass, B.A.; Hassen, A.E.; Agegnehu, A.F.; Temesgen, M.M.; Gebeyehu, N.A.; Ferede, Y.A.; Tegegne, B.A. Management of perioperative anaphylaxis: Systematic review. Int. J. Surg. Open 2023, 52, 100595. [Google Scholar] [CrossRef]
| Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).